Lillyās Taltz and Zepbound Show One-Year Benefits
Indianapolis, Indiana, August 31, 2026 Eli Lilly and Company announced new Phase 3b data showing that treatment with TaltzĀ®...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Indianapolis, Indiana, August 31, 2026 Eli Lilly and Company announced new Phase 3b data showing that treatment with TaltzĀ®...
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
